Human Molecular Genetics, 2001, Vol. 10, No. 15 1547-1554
© 2001 Oxford University Press
Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells
Department of Human and Clinical Genetics, Leiden University Medical Center, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands and 1Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands
Due to frame-shifting mutations in the DMD gene that cause dystrophin deficiency, Duchenne muscular dystrophy (DMD) patients suffer from lethal muscle degeneration. In contrast, mutations in the allelic Becker muscular dystrophy (BMD) do not disrupt the translational reading frame, resulting in a less severe phenotype. In this study, we explored a genetic therapy aimed at restoring the reading frame in muscle cells from DMD patients through targeted modulation of dystrophin pre-mRNA splicing. Considering that exon 45 is the single most frequently deleted exon in DMD, whereas exon (45+46) deletions cause only a mild form of BMD, we set up an antisense-based system to induce exon 46 skipping from the transcript in cultured myotubes of both mouse and human origin. In myotube cultures from two unrelated DMD patients carrying an exon 45 deletion, the induced skipping of exon 46 in only 
15% of the mRNA led to normal amounts of properly localized dystrophin in at least 75% of myotubes. Our results provide first evidence of highly effective restoration of dystrophin expression from the endogenous gene in DMD patient-derived muscle cells. This strategy may be applicable to not only >65% of DMD mutations, but also many other genetic diseases.
+ To whom correspondence should be addressed. Tel: +31 71 5276080; Fax: +31 71 5276075; Email: deutekom@lumc.nl
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. C. van Deutekom, A. A. Janson, I. B. Ginjaar, W. S. Frankhuizen, A. Aartsma-Rus, M. Bremmer-Bout, J. T. den Dunnen, K. Koop, A. J. van der Kooi, N. M. Goemans, et al. Local Dystrophin Restoration with Antisense Oligonucleotide PRO051 N. Engl. J. Med., December 27, 2007; 357(26): 2677 - 2686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-F. Chang, W.-K. Chan, J. S. Imam, and M. F. Wilkinson Alternatively Spliced T-cell Receptor Transcripts Are Up-regulated in Response to Disruption of Either Splicing Elements or Reading Frame J. Biol. Chem., October 12, 2007; 282(41): 29738 - 29747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aartsma-Rus and G.-J. B. van Ommen Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications RNA, October 1, 2007; 13(10): 1609 - 1624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hirata, T. Watanabe, J. Hatakeyama, S. M. Sprague, L. Saint-Amant, A. Nagashima, W. W. Cui, W. Zhou, and J. Y. Kuwada Zebrafish relatively relaxed mutants have a ryanodine receptor defect, show slow swimming and provide a model of multi-minicore disease Development, August 1, 2007; 134(15): 2771 - 2781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Du, J. M. Pollard, and R. A. Gatti Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides PNAS, April 3, 2007; 104(14): 6007 - 6012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bertoni, G. E. Morris, and T. A. Rando Strand bias in oligonucleotide-mediated dystrophin gene editing Hum. Mol. Genet., January 15, 2005; 14(2): 221 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Mendell and A. Miller Gene transfer for neurologic disease: Agencies, policies, and process Neurology, December 28, 2004; 63(12): 2225 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M Selkirk Gene therapy in clinical medicine Postgrad. Med. J., October 1, 2004; 80(948): 560 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Gebski, C. J. Mann, S. Fletcher, and S. D. Wilton Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle Hum. Mol. Genet., August 1, 2003; 12(15): 1801 - 1811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bertoni, C. Lau, and T. A. Rando Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping Hum. Mol. Genet., May 15, 2003; 12(10): 1087 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aartsma-Rus, A. A.M. Janson, W. E. Kaman, M. Bremmer-Bout, J. T. den Dunnen, F. Baas, G.-J. B. van Ommen, and J. C.T. van Deutekom Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients Hum. Mol. Genet., April 15, 2003; 12(8): 907 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Squire, J.M. Raymackers, C. Vandebrouck, A. Potter, J. Tinsley, R. Fisher, J.M. Gillis, and K.E. Davies Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system Hum. Mol. Genet., December 15, 2002; 11(26): 3333 - 3344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Chamberlain Gene therapy of muscular dystrophy Hum. Mol. Genet., October 1, 2002; 11(20): 2355 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. De Angelis, O. Sthandier, B. Berarducci, S. Toso, G. Galluzzi, E. Ricci, G. Cossu, and I. Bozzoni Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells PNAS, July 9, 2002; 99(14): 9456 - 9461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dias and C. A. Stein Antisense Oligonucleotides: Basic Concepts and Mechanisms Mol. Cancer Ther., March 1, 2002; 1(5): 347 - 355. [Full Text] [PDF]
|
|
|
|
 |
|
 C Francannet, A Cohen-Tanugi, M Le Merrer, A Munnich, J Bonaventure, and L Legeai-Mallet Genotype-phenotype correlation in hereditary multiple exostoses J. Med. Genet., July 1, 2001; 38(7): 430 - 434. [Abstract] [Full Text] [PDF]
|
|